Thickness, μm | 0 (N=256) | 1 (N=241) | 2 (N=47) | Total (N=544) | P value |
ChT-Centre | 218±55 | 161±40 | 109±39 | 183±59 | <0.001 a, b, c |
ChT-In-S | 232±53 | 176±41 | 121±38 | 197±59 | <0.001 a, b, c |
ChT-In-I | 219±52 | 164±37 | 113±37 | 185±56 | <0.001 a, b, c |
ChT-In-N | 194±51 | 140±37 | 88±29 | 161±55 | <0.001 a, b, c |
ChT-In-T | 233±53 | 180±40 | 129±41 | 201±58 | <0.001 a, b, c |
ChT-Out-S | 238±49 | 186±42 | 129±35 | 206±57 | <0.001 a, b, c |
ChT-Out-I | 212±49 | 163±36 | 111±34 | 182±53 | <0.001 a, b, c |
ChT-Out-N | 151±44 | 108±32 | 63±19 | 125±47 | <0.001 a, b, c |
ChT-Out-T | 239±49 | 193±38 | 146±40 | 211±52 | <0.001 a, b, c |
RT-Centre | 233±19 | 229±21 | 222±22 | 230±21 | <0.001 a, b |
RT-In-S | 303±15 | 296±20 | 289±19 | 299±18 | <0.001 a, b, c |
RT-In-I | 301±16 | 294±19 | 291±23 | 297±18 | <0.001 a, b |
RT-In-N | 304±16 | 296±16 | 289±19 | 299±17 | <0.001 a, b, c |
RT-In-T | 292±15 | 283±21 | 278±19 | 287±19 | <0.001 a, b |
RT-Out-S | 270±15 | 266±17 | 261±16 | 267±16 | <0.001 a, b |
RT-Out-I | 253±14 | 249±16 | 246±20 | 251±16 | 0.003 a, b |
RT-Out-N | 282±14 | 276±16 | 272±17 | 278±16 | <0.001 a, b |
RT-Out-T | 254±14 | 249±18 | 247±17 | 251±16 | 0.001 a, b |
Statistical significance was tested using analysis of variance, and the Bonferroni method was used for post hoc tests. Statistical significance was defined as p<0.05 (two tailed).
For post hoc tests, superscript a refers to significant difference between group 0 and group 1 (p<0.05), superscript b refers to significant difference between group 0 and group 2 (p<0.05), and superscript c refers to significant difference between group 1 and group 2 (p<0.05).
Group 0—without myopic maculopathy; group 1—tessellated fundus; group 2—diffuse chorioretinal atrophy.
Centre, central fovea; ChT, choroidal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; I, inferior; In, inner circle of the ETDRS grid; N, nasal; Out, outer circle of the ETDRS grid; RT, retinal thickness; S, superior; T, temporal.